Yuanfang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuanfang Chen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Haikang Tang
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
1 shared publication Jiawei Luo
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
1 shared publication- Luntao Liu
State Key Laboratory of Advanced Medical Materials and Devices Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine Tianjin Institutes of Health Science Institute of Radiation Medicine Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin P. R. China
1 shared publication Qingqing Wang
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
1 shared publicationQinyi Gui
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
1 shared publicationShuangjiao Sun
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
1 shared publication
Latest Publications
- 7 April 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 215, 317-335
Salmonella biomimetic Janus nanorobots reinvigorate colorectal cancer radio-immunotherapy by glycolysis inhibition and cGAS-STING activation
- 7 April 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 215, 317-335
Salmonella biomimetic Janus nanorobots reinvigorate colorectal cancer radio-immunotherapy by glycolysis inhibition and cGAS-STING activation
- Open Access
- 29 October 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (11) , 2145
ROS-Responsive and pH-Sensitive Aminothiols Dual-Prodrug for Radiation Enteritis
Radiation exposure can immediately trigger a burst of reactive oxygen species (ROS), which can induce severe cell death and long-term tissue damage. Therefore, instantaneous release of sufficient radioprotective drugs is vital to neutralize those accumulated ROS in IR-exposed areas. To achieve this goal, we designed, synthesized, and evaluated a novel oral ROS-responsive radioprotective compound (M1) with high biocompatibility and efficient ROS-scavenging ability to act as a promising oral drug for radiation protection. The compound is stably present in acidic environments and is hydrolyzed in the intestine to form active molecules rich in thiols. M1 can significantly remove cellular ROS and reduce DNA damage induced by γ-ray radiation. An in vivo experiment showed that oral administration of M1 effectively alleviates acute radiation-induced intestinal injury. Immunohistochemical staining showed that M1 improved cell proliferation, reduced cell apoptosis, and enhanced the epithelial integrity of intestinal crypts. This study provides a promising oral ROS-sensitive agent for acute intestinal radiation syndrome.
- 29 October 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (11) , 2145
Open AccessROS-Responsive and pH-Sensitive Aminothiols Dual-Prodrug for Radiation Enteritis
Radiation exposure can immediately trigger a burst of reactive oxygen species (ROS), which can induce severe cell death and long-term tissue damage. Therefore, instantaneous release of sufficient radioprotective drugs is vital to neutralize those accumulated ROS in IR-exposed areas. To achieve this goal, we designed, synthesized, and evaluated a novel oral ROS-responsive radioprotective compound (M1) with high biocompatibility and efficient ROS-scavenging ability to act as a promising oral drug for radiation protection. The compound is stably present in acidic environments and is hydrolyzed in the intestine to form active molecules rich in thiols. M1 can significantly remove cellular ROS and reduce DNA damage induced by γ-ray radiation. An in vivo experiment showed that oral administration of M1 effectively alleviates acute radiation-induced intestinal injury. Immunohistochemical staining showed that M1 improved cell proliferation, reduced cell apoptosis, and enhanced the epithelial integrity of intestinal crypts. This study provides a promising oral ROS-sensitive agent for acute intestinal radiation syndrome.